Heartseed
CompanyJapan
Heartseed develops 2 assets, the furthest in phase 1 (HS-001 in heart failure). Mostly cell therapy; based in Japan.
- 2
- Assets
- Furthest stage
- Phase 1
- 2
- Trials
- 0
- Signals
Pipeline
2Transplanted allogeneic iPSC-derived cardiomyocyte spheroids regenerate heart muscle to improve cardiac function.
Phase 1, Cell therapy, heart failure, ischemic heart disease
Transplanted allogeneic iPSC-derived cardiomyocyte spheroids regenerate heart muscle to improve cardiac function.
Phase 1, Cell therapy, dilated cardiomyopathy, heart failure
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Trials2
- Signals1
- Similar companies6